Today, less than five percent of the 50 to 60 million U.S. allergy sufferers receive the benefit of immunotherapy — the only treatment that addresses the root cause of allergies.
Clinical experience shows, and research validates, that sublingual immunotherapy’s safety and convenience profile broadens the range of candidates for immunotherapy beyond traditional injection immunotherapy. Today, allergy practices can offer patients an additional choice for a long-term allergy solution.
Allergychoices can help your practice integrate sublingual immunotherapy using the La Crosse Method™ Protocol — blending European and U.S. sublingual immunotherapy traditions and research — with more than 40 years of practical clinical experience. Learn why more sublingual immunotherapy providers are choosing to help more patients using the services and expertise of the leaders in the U.S.
Learn more about sublingual immunotherapy by viewing the video below.
In order to view the content, you must install the Adobe Flash Player. Please click here
to get started.
Visit eyemaginations.com for more information about incorporating Eyemaginations patient education modules in your practice.